Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Ahuja TS. Berns JS, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Kajiyama H, Winkler CA. Genome wide admixture mapping identifies MYH9 as a major effect risk gene for focal segmental glomerulosclerosis. Nature Genetics 40: 1175-1184, 2008.
Kajiyama J, Titus S, Austin C, Chiotos K, Matsumoto T, Sakairi T, Kopp JB. Tetracyclne-inducible gene expression in conditionally immortalized mouse podocytes. Am J Nephrol 29:153-163, 2008.
Shrivastav S, Kino T, Schubert U, Heinklein P, Chrousos G, Kopp JB. HIV-1 Vpr suppresses the transcriptional activity of PPAR-gamma and inhibits adipocyte differentiation: Implications for HIV-associated lipodystrophy. Mol Endocrinol 22:234-247, 2008.
Cho M, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2:906-13, 2007.
McKenzie LM, Hendrickson SL, Briggs WA, Dart RA, Korbet SM, Mokrzycki MH, Kimmel PL, Ahuja TS, Berns JS, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Cho M, Zhou YC, Binns-Roemer E, Kirk GD, Kopp JB, and Winker CA. Role of NPHS2 variation in sporadic FSGS: A common haplotype is protective and heterozygosity for R138Q is a risk factor. J Am Soc Nephrol, 18: 2987-2995, 2007.
Balasubramanyam A, Mersmann H, Jahoor F, Phillips T, Schubert U, Brar B, Iyer D, Smith EO, Takahashi H, Lu H, Kopp JB. Effects of transgenic expression of HIV-1 protein Vpr on energy metabolism in mice. Am J Physiol 292:E40-48, 2007.
Cho M, Hurley J, Kopp JB. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis, 49:310-17, 2007
Xu Q, Norman JT, Shrivastav S, Lucio-Cazana J, Kopp JB. Cell-based models of TGF-beta induced fibrogenesis for high-throughput screening of anti-fibrotic agents. Am J Physiol 293:F631-40, 2007.
Reviews and book chapters
Cho ME, Kopp JB. Pirfenidone: an anti-fibrotic and cytoprotective agent as therapy for progressive kidney disease. Expert Opin Invest Drugs, in press.
Kopp JB, Fabian J, Naicker S. HIV infection and the kidney. Comprehensive Clinical Nephrology, RJ Johnson and J Feehally. Third Edition, 2009.
Marasa M, Kopp JB. Monoclonal antibodies as therapy for the podocytopathies: biologic rationale and clinical responses. Nature Clin Pract Nephrol 2009:337-348, 2009.
Barisoni L, Schnaper HW, Kopp JB. Advances in the biology and genetics of the podocytopathies: implications for diagnosis and management. Arch Pathol 133:201-216, 2008.
Waldman M, Marshall V, Whitby D, Kopp JB. Viruses and kidney disease: beyond HIV. Sem Nephrol 28:595-607, 2008.
Woronie R, Kopp JB. Genetics of focal segmental glomerulosclerosis. Pediatr Nephrol 5:638-644, 2007.
Barisoni L, Schnaper HW, Kopp JB. A working classification of podocytopaties integrating morphologic and etiologic criteria. C J Am Soc Nephrol 2:529-542, 2007.
Kopp JB, Ball LK, Cohen A, Kenney RJ, Lempert KD, Miller PE, Muntner P, Qureshi N, Yelton SA. Kidney Patient care in disasters: lessons from the hurricanes and earthquake of 2005. Clin J Am Soc NephroL 2:814-824, 2007.
Kopp JB, Ball LK, Cohen A, Kenney RJ, Lempert KD, Miller PE, Muntner P, Qureshi N, Yelton SA. Kidney Patient care in disasters: Emergency planning for patients and dialysis facilities. Clin J Am Soc Nephrol 2:825-838, 2007.
Waldman M, Kopp JB. Parvovirus B19 and kidney disease. Clin J Am Soc Nephrol 2 Suppl 1:S47-56, 2007.
Waldman M, Kopp JB. Parvovirus B19-associated complications in renal transplant recipients. Nat Clin Pract Nephrol 3:540-550, 2007.